Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months

Background and Objective: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects its therapeutic effects. Furthermore, because patients treated with sorafenib for a long period can presumably to...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Case Reports in Oncology
المؤلفون الرئيسيون:	Kazuhiro Katayama, Ryosuke Kiyota, Toshihiro Imai, Yutaro Abe, Tadatoshi Nawa, Hiroshi Wada, Kazuyoshi Ohkawa
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Karger Publishers 2018-11-01
الموضوعات:	Hepatocellular carcinoma Sorafenib Adverse events Long-term survival
الوصول للمادة أونلاين:	https://www.karger.com/Article/FullText/493853